Please assess the completion status of the following clinical trial:

Trial Title: Pilot Feasibility Study With Patients Who Are at High Risk For Developing Invasive Candidiasis in a Critical Care Setting (MK-0991-067)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Hospitalization for a minimum of 3 days in an ICU and expectation to stay in the ICU for at least another 48 hours~* Meets the following high-risk criteria: Requires mechanical ventilation at the time of study entry; and has a central venous catheter in place at the time of study entry; and is receiving broad spectrum antibiotics at the time of study entry; AND meets at least one of the following criteria: Required parenteral nutrition during the current ICU admission; or required renal dialysis during the current ICU admission; or had major surgery during or within the 7 days before the current ICU admission; or was diagnosed with pancreatitis during or within the 7 days before the current ICU admission; or required systemic steroids or other immunosuppressive agents during or within the 7 days before the current ICU admission~* Meets at least one of the following criteria of suspected infection at the time of study entry or within the 24 hours before study entry: Temperature ≥38° C or ≤36° C (oral equivalent); or hypotension (systolic blood pressure of \<90 mm Hg) or significant drop in blood pressure (40 mm Hg) from the participant's normal baseline; or elevated white blood cell count of ≥12,000/mm\^3~* Candida is growing in at least one non-sterile culture site collected during the current ICU admission~* Female of childbearing potential has a negative serum or urine pregnancy test before enrollment~Exclusion Criteria:~* Females pregnant or breast feeding~* History of allergy, hypersensitivity, or any serious reaction to caspofungin or another member of the echinocandin class (e.g., micafungin, anidulafungin)~* Neutropenia or expected to develop neutropenia during study therapy~* Diagnosis of acquired immune deficiency syndrome (AIDS), aplastic anemia, or chronic granulomatous disease~* Diagnosis of moderate or severe hepatic insufficiency~* Patient not expected to survive at least 24 hours~* Received systemic (IV or oral) antifungal therapy within 10 days before study entry~* Active diagnosis of proven or probable invasive fungal infection (IFI)~* Currently on or has received an investigational agent within 10 days before study entry~* Any condition or concomitant illness which might confuse the study results or pose additional risk in administering the study therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Caspofungin (Type: EXPERIMENTAL): caspofungin acetate
- Placebo (Type: PLACEBO_COMPARATOR): normal saline

Based on this trial design, predict the completion outcome and termination type (if applicable).